Table 2 Variables for the evaluation of bone metabolism
From: Bone damage after chemotherapy for lymphoma: a real-world experience
|  | No. (%) | Mean ± SD | |
|---|---|---|---|
Vitamin D (ng/ml) | Normal (31–100) | 5 (17,2) | 21.6 ± 8.8 |
Insufficiency (11–30) | 22 (75,9) | ||
Deficiency (≤10) | 2 (6,9) | ||
PTH (pg/ml) | High (> 70) | 6 (20,7) | 43.5 ± 26.8 |
Normal (12–70) | 20 (69,0) | ||
Low (< 12) | 3 (10,3) | ||
BMD Femural (g/cm2) |  |  | 0.9 ± 0.1 |
T-Score Femural | Normal | 15 (55,6) | −0.8 ± 1.2 |
Osteopenia | 10 (37,0) | ||
Osteoporosis | 2 (7,4) | ||
Z-Score Femural |  |  | −0.1 ± 1.1 |
BMD Lumbar Vertebral |  |  | 0.9 ± 0.2 |
T-Score Lumbar Vertebral | Normal | 14 (50,0) | −1.0 ± 1.5 |
Osteopenia | 7 (25,0) | ||
Osteoporosis | 7 (25,0) | ||
Z-Score Lumbar Vertebral |  |  | −0.2 ± 1.4 |
Vertebral Fractures | No | 10 (34,5) | 2.1 ± 1.8 |
1 or 2 | 10 (34,5) | ||
≥3 | 9 (31,0) | ||
SARC-F | ≥4 (sarcopenic) | 18 (62) | 3.8 ± 1.9 |
< 4 (non sarcopenic) | 11 (38) | ||
Mini OQoL | Mild | 11 (37,9) | Â |
|  | Moderate | 16 (55,2) | 54.4 ± 11.1 |
| Â | Severe | 2 (6,9) | Â |